Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company dedicated to discovering, developing, and delivering potentially curative therapies that address the underlying causes of heart disease. Founded in 2016 and headquartered in South San Francisco, Tenaya Therapeutics leverages its integrated platforms in Gene Therapy, Cellular Regeneration, and Precision Medicine to advance a pipeline of novel therapeutic candidates targeting both rare genetic cardiovascular disorders and more prevalent heart conditions.
Tenaya's flagship programs include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF). In late October 2023, the company announced the U.S. FDA clearance of its Investigational New Drug (IND) application for TN-401, initiating the RIDGE-1 Phase 1b clinical trial to evaluate its safety, tolerability, and efficacy.
Tenaya is a preclinical-stage company but has made significant strides. Its gene therapy TN-401 aims to treat ARVC by delivering a fully functional PKP2 gene to restore protein levels necessary for heart muscle function. The company also focuses on genetic mutations responsible for heart diseases, aiming to reverse or halt disease progression efficiently.
The company’s commitment to innovation extends to its robust pipeline and strategic collaborations, ensuring progress in addressing unmet needs in cardiac care. With a fully operational Genetic Medicines Manufacturing Center, Tenaya can produce clinical trial material at scale, highlighting its readiness to transition groundbreaking research into clinical applications.
For the latest updates, detailed financial results, and corporate announcements, visit their official website at www.tenayatherapeutics.com.
FAQ
What is the current stock price of Tenaya Therapeutics (TNYA)?
The current stock price of Tenaya Therapeutics (TNYA) is $1.26 as of January 23, 2025.
What is the market cap of Tenaya Therapeutics (TNYA)?
The market cap of Tenaya Therapeutics (TNYA) is approximately 99.4M.
What is Tenaya Therapeutics, Inc.?
Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing curative therapies for heart diseases, leveraging gene therapy, cellular regeneration, and precision medicine platforms.
What is TN-401?
TN-401 is an investigational gene therapy developed by Tenaya targeting arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. It aims to restore normal protein levels in heart cells.
When was Tenaya Therapeutics established?
Tenaya Therapeutics was founded in 2016.
What are the main therapeutic programs of Tenaya Therapeutics?
Tenaya's main programs include TN-201 for hypertrophic cardiomyopathy (HCM), TN-401 for arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301 for heart failure with preserved ejection fraction (HFpEF).
Where is Tenaya Therapeutics located?
Tenaya Therapeutics is headquartered in South San Francisco, California.
What recent milestones has Tenaya Therapeutics achieved?
Recent milestones include FDA clearance for the TN-401 IND application and the initiation of the RIDGE-1 Phase 1b clinical trial.
What is the goal of TN-301?
TN-301 is a small molecule HDAC6 inhibitor aiming to treat heart failure with preserved ejection fraction (HFpEF) by improving cardiac function and reducing inflammation and fibrosis.
How is Tenaya Therapeutics advancing its therapies?
Tenaya advances its therapies through integrated gene therapy, cellular regeneration, and precision medicine platforms, supported by proprietary manufacturing capabilities.
What is the significance of the RIDGE-1 Phase 1b clinical trial?
The RIDGE-1 Phase 1b clinical trial evaluates the safety, tolerability, and efficacy of a one-time intravenous infusion of TN-401 in patients with PKP2-associated ARVC.
How can I get more information about Tenaya Therapeutics?
For more information, you can visit the official website of Tenaya Therapeutics at www.tenayatherapeutics.com.